Autoimmune connective tissue diseases in the COVID-19 pandemic
| Autor: | Snejina Vassileva, Lyubomir Dourmishev, Dimitrina Guleva, L. Miteva, Kossara Drenovska, Joana Pozharashka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Vasculitis
Connective tissue Dermatology Antibodies Monoclonal Humanized Article Scleroderma Dermatomyositis 030207 dermatology & venereal diseases 03 medical and health sciences Antimalarials 0302 clinical medicine Immune system Thromboembolism medicine Macrophage Humans Janus Kinase Inhibitors Lupus Erythematosus Systemic 030203 arthritis & rheumatology Lupus erythematosus Scleroderma Systemic biology business.industry SARS-CoV-2 Patient Acuity COVID-19 medicine.disease medicine.anatomical_structure Immunology biology.protein Disease Susceptibility business Elastin Immunosuppressive Agents Hydroxychloroquine |
| Zdroj: | Clinics in Dermatology |
| ISSN: | 1879-1131 |
| Popis: | Autoimmune connective tissue diseases are a heterogeneous group of clinical entities sharing a common feature-an impairment of structural components like collagen and elastin, arising by autoimmune mechanisms. Because most patients are on a long-term immunosuppressive therapy, which renders them vulnerable to infections, a new challenge appears in front of physicians in the coronavirus disease 2019 (COVID-19) era. Immune mechanisms are substantial for the control and ceasing of viral infections, and their impairment may cause serious complications; however, data from immunosuppressed transplant patients do not reveal a higher frequency or diseases’ severity in those infected by COVID-19. Several immunotherapies used to treat autoimmune connective tissue diseases favorably modulate the immune response of severe acute respiratory syndrome coronavirus (SARS-CoV-2)–infected patients. The present review highlights the problems of susceptibility, severity, and therapeutic options in patients with autoimmune connective tissue diseases during the COVID-19 pandemic. The relationship between autoimmune connective tissue diseases and COVID-19 infection is explained with antiviral protection genes expression, hypercytokinemia, and lymphohistiocytosis/macrophage activation mechanisms. Recommendations concerning therapy for prevention during the pandemic period or in case of concomitant COVID-19 infection are also presented. Clinical trials are ongoing regarding COVID-19 therapy blocking the cytokine response. © 2021 Elsevier Inc. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect